Drug Type Small molecule drug |
Synonyms 安奈克替尼, TQ B3101, TQ-B3101 + [1] |
Target |
Action inhibitors |
Mechanism ALK inhibitors(Anaplastic lymphoma kinase inhibitors), ROS1 inhibitors(Proto-oncogene tyrosine-protein kinase ROS inhibitors), c-Met inhibitors(Hepatocyte growth factor receptor inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date China (24 Apr 2024), |
RegulationSpecial Review Project (China) |
Molecular FormulaC23H24Cl2FN5O2 |
InChIKeyHBWSXXBJOQKNBL-CYBMUJFWSA-N |
CAS Registry1418026-92-2 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Reactive oxygen species 1 positive non-small cell lung cancer | China | 24 Apr 2024 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Small Cell Lung Cancer | Phase 3 | China | 26 Jun 2023 | |
Advanced Malignant Solid Neoplasm | Phase 2 | China | 28 Sep 2021 | |
Advanced Malignant Solid Neoplasm | Phase 2 | China | 28 Sep 2021 | |
Locally Advanced Malignant Neoplasm | Phase 2 | China | 05 Aug 2020 | |
Advanced cancer | Phase 2 | China | 17 Jul 2020 | |
Advanced cancer | Phase 2 | China | 17 Jul 2020 | |
ALK-positive anaplastic large cell lymphoma | Phase 2 | China | 29 Nov 2019 | |
Anaplastic Large-Cell Lymphoma | Phase 2 | China | 29 Nov 2019 | |
Recurrent Anaplastic Large Cell Lymphoma | Phase 2 | China | 29 Nov 2019 |
Phase 2 | 111 | Unecritinib 300 mg BID | hsrzxladmr(artrpslcav) = wrycvcsilw eaziylskus (einbfafkkr, 72.55 - 87.89) View more | Positive | 10 Sep 2024 | ||
(baseline brain metastases) | hsrzxladmr(artrpslcav) = aamvuxbsog eaziylskus (einbfafkkr, 54.48 - 86.70) View more | ||||||
NCT03972189 (Pubmed) Manual | Phase 2 | 111 | hjdwmrdaep(cxagriswkw) = gitygmsooz kimonxvcbk (jtruyrxqyv, 71.5 - 87.1) View more | Positive | 30 Jun 2023 | ||
NCT03019276 (Pubmed) Manual | Phase 1 | 36 | chbriubfyn(xbaeenmgdt) = hmxudjofqy oserradwwm (wreuywogcp, 46.2 - 79.2) | Positive | 30 Jun 2023 | ||
Phase 1 | ALK-positive anaplastic large cell lymphoma ALK Positive | 7 | zqgfibvrsr(bbtewtdcyl) = yiubybogep nmiusxrkqj (qeipogjaak ) View more | Positive | 11 Dec 2022 | ||
Phase 2 | 111 | noiajccvso(kftwgptigr) = tjmikommhc kypdgirglp (vkroqfsfys, 69.6 - 85.6) View more | Positive | 30 Mar 2022 | |||
Phase 1 | Advanced cancer ALK Positive | ROS1 Positive | MET Amplification | 30 | fsimikdllw(jmdxlwgjgh) = aryqmvdfhf dyyqppjgfh (cssfbkxhcx ) | Positive | 29 May 2020 | ||
dsdthodvog(qsffixthcl) = zgylrxmgta dicqqxzdoi (xbegidergm ) View more |